Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens
PARPi efficacy depends strongly on BRCA and HRD status. Olaparib-based regimens provide the greatest clinical benefit with acceptable safety in BRCA+ and HRD+ disease, whereas PARPi appear to be of limited value in HRD-negative ovarian cancer.
Authors
- Andrea Messori (ORCID: https://orcid.org/0000-0002-5829-107X)
- Vera Damuzzo (ORCID: https://orcid.org/0000-0002-3685-6789)
- Luca Cancanelli (ORCID: https://orcid.org/0000-0002-6409-4195)
- Andrea Ossato (ORCID: https://orcid.org/0000-0001-8984-4733)
- Lorenzo Gasperoni (ORCID: https://orcid.org/0000-0001-6427-0809)
- Stefano Vecchia (ORCID: https://orcid.org/0000-0003-0578-0870)
- Caterina Fontanella
- Luna Del Bono
Institutions
- University of Pisa (IT)
- AULSS 2 Marca Trevigiana (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Italian Society of Physiotherapy (IT)
- Guglielmo da Saliceto Hospital (IT)
- Ospedale Civile di Vittorio Veneto (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3390/cancers17223714
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00